ghrelin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
=== Mental health and Dementia === Mental health conditions are common in people living with dementia. Depression and anxiety frequently occur alongside cognitive decline, and can worsen day‑to‑day functioning and quality of life. People with dementia who experience co‑morbid depression or anxiety are at increased risk of suicidal ideation, suicide attempts, and death by suicide, particularly in the earlier stages of dementia. Some groups appear to have an even higher likelihood of developing mood problems. For example, frontotemporal dementia is often associated with early behavioural and emotional changes, and people with young‑onset dementia (where symptoms begin before age 65) may be more vulnerable to depression and anxiety because of the impact on employment, identity, and family roles. Mental health conditions in people living with dementia are often under-recognised and undertreated. Untreated depression and anxiety can contribute to distress, behavioural changes, greater care needs and an increased risk of admission to long‑term care. However, it is not inevitable that people with dementia will experience mood problems. When symptoms occur, they can be assessed as for those living without dementia. Non‑drug approaches—such as psychological therapies, social engagement, and activity‑based interventions are recommended as first‑line treatments, with medication reserved for specific situations. Research also suggests that mental health difficulties earlier in life may be linked to later dementia risk.
Heroin is generally a preferred product for smuggling and distribution—over unrefined opium due to the cost-effectiveness and increased efficacy of heroin. Because of the high cost per volume, heroin is easily smuggled. A US quarter-sized (2.5 cm) cylindrical vial can contain hundreds of doses. From the 1930s to the early 1970s, the so-called French Connection supplied the majority of US demand. Allegedly, during the Vietnam War, drug lords such as Ike Atkinson used to smuggle hundreds of kilograms of heroin to the US in coffins of dead American soldiers (see Cadaver Connection). Since that time it has become more difficult for drugs to be imported into the US than it had been in previous decades, but that does not stop the heroin smugglers from getting their product across US borders. Purity levels vary greatly by region with Northeastern cities having the most pure heroin in the United States. On 17 October 2018 police in Genoa, Italy discovered 270 kg (600 lb) of heroin hidden in a ship coming from the Iranian southern port of Bandar Abbas. The ship had already passed and stopped at Hamburg in Germany and Valencia in Spain. Penalties for smuggling heroin or morphine are often harsh in most countries. Some countries will readily hand down a death sentence (e.g. Singapore) or life in prison for the illegal smuggling of heroin or morphine, which are both internationally Schedule I drugs under the Single Convention on Narcotic Drugs. In May 2021, Romania seized 1.4 tonnes of heroin at Constanța port of a shipment from Iran that was headed for Western Europe.
Synthesis during the formation of the universe is the only significant way naturally occurring deuterium has been created; it is destroyed in stellar fusion. Deuterium is thought to have played an important role in setting the number and ratios of the elements that were formed in the Big Bang. Combining thermodynamics and the changes brought about by cosmic expansion, one can calculate the fraction of protons and neutrons based on the temperature at the point that the universe cooled enough to allow formation of nuclei. This calculation indicates seven protons for every neutron at the beginning of nucleogenesis, a ratio that would remain stable even after nucleogenesis was over. This fraction was in favor of protons initially, primarily because the lower mass of the proton favored their production. As the Universe expanded, it cooled. Free neutrons and protons are less stable than helium nuclei, and the protons and neutrons had a strong energetic reason to form helium-4. However, forming helium-4 requires the intermediate step of forming deuterium. Through much of the few minutes after the Big Bang during which nucleosynthesis could have occurred, the temperature was high enough that the mean energy per particle was greater than the binding energy of weakly bound deuterium; therefore, any deuterium that was formed was immediately destroyed. This situation is known as the deuterium bottleneck. The bottleneck delayed formation of any helium-4 until the Universe became cool enough to form deuterium (at about a temperature equivalent to 100 keV).
Sources: en.wikipedia.org
== Atrial fibrillation == Pulmonary vein isolation has been the mainstay of atrial fibrillation reduction, but in many cases there are other sources of arrhythmia, including the LoM. Use of ethanol through the VoM has been shown to be an effective way to reduce atrial fibrillation.
As nitrogen is an asphyxiant gas in itself, some jurisdictions have considered asphyxiation by inhalation of pure nitrogen as a means of capital punishment (as a substitute for lethal injection). In January 2024, Kenneth Eugene Smith became the first person executed by nitrogen asphyxiation.
The above reactions are balanced if Pi represents the H2PO4− ion, ADP and GDP the ADP2− and GDP2− ions, respectively, and ATP and GTP the ATP3− and GTP3− ions, respectively. The total number of ATP molecules obtained after complete oxidation of one glucose in glycolysis, citric acid cycle, and oxidative phosphorylation is estimated to be between 30 and 38.
The United Kingdom was represented by its 1st Armoured Division known as the Desert Rats. The British 1st Armoured Division fielded approximately 176 Challenger 1 tanks. British infantry rode into battle on the Warrior tracked armoured vehicle. It had reasonable armour protection and a 30mm gun. Modified versions of the vehicle included mortar carriers, MILAN antitank systems, and command and control vehicles; and the British possessed a variety of excellent light armoured vehicles built on their FV101 Scorpion chassis. British artillery was primarily American made M109 howitzers (155mm), M110 howitzers (203mm), and M270 MLRS which were compatible with American systems. Their air support consisted of Gazelle helicopters, used for reconnaissance, and the Lynx helicopter which was comparable to the American AH-1 Cobra. The British had their full contingent of engineer, logistics, and medical units. The British 1st Armoured Division was responsible for protecting the right flank of VII Corps. It was assumed by the Corps' planners the Iraqi 52nd Armored Division would counterattack VII Corps once their penetration into Iraqi defenses was discovered. The British 1st Armoured Division had two brigades (the 4th and 7th) which participated in Operation Granby, the name given to the British military operations during the 1991 Gulf War. The British 1st Armoured Division had traveled 217 miles in 97 hours. The British 1st Armoured Division had captured or destroyed about 300 Iraqi tanks and a very large number of armored personnel carriers, trucks, reconnaissance vehicles, etc.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.